MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.945
+0.035
+1.83%
Opening 09:55 03/02 EST
OPEN
1.950
PREV CLOSE
1.910
HIGH
1.960
LOW
1.920
VOLUME
151.32K
TURNOVER
--
52 WEEK HIGH
2.980
52 WEEK LOW
1.010
MARKET CAP
88.40M
P/E (TTM)
-1.6328
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellectar Biosciences shares rise after FY results
Cellectar Biosciences (CLRB) shares rise nearly 5% premarket after the company talked up its cash position and posted full-year results. The company had cash and cash equivalents of $57.2M compared to $10.6M at December
Seekingalpha · 51m ago
Press Release: Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
Dow Jones · 1h ago
8-K: Cellectar Biosciences, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 8-K ___________________ CURRENT REPORT (EDGAR Online via...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
3 Penny Stocks To Buy Under $2 & Analysts Have Targets Up To 367%
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Say These Are Penny Stocks To Buy; Do You Agree? We talk a lot about penny stocks for obvious reasons. But...
Penny Stocks · 5d ago
Interest in Cellectar increases with private equity purchases
Interest in Cellectar Biosciences (CLRB) from private equity firms this week jumped this week as evidenced by several SEC Form 13G and Form 13G/A amended filings.This week, Consonance Capital Management and Sio
Seekingalpha · 02/19 15:41
Von Hippel-Lindau Treatment Market Industry Analysis, Size, Share ,Growth, Trends and Forecast 2020-2027 by Ameco Research
Comserve · 02/19 06:13
8-K: Cellectar Biosciences, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- PURSUANT TO SECTION 13 OR 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/10 21:47
Cellectar to Present at BIO CEO & Investor Digital Conference
FLORHAM PARK, N.J., Feb 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:...
GlobeNewswire · 02/10 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLRB. Analyze the recent business situations of Cellectar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLRB stock price target is 5.98 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 18.48M
% Owned: 40.66%
Shares Outstanding: 45.45M
TypeInstitutionsShares
Increased
6
3.16M
New
31
11.26M
Decreased
2
173.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
-0.04%
Key Executives
Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer/Vice President
Dov Elefant
Vice President
John Friend
Other
Jarrod Longcor
Independent Director
Frederick Driscoll
Independent Director
Stephen Hill
Independent Director
Stefan Loren
Independent Director
John Neis
  • Dividends
  • Splits
  • Insider Activity
No Data
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.